Recent advances in the treatment of advanced NSCLC include the identification and successful targeting of specific molecular abnormalities such as mutations of the epidermal growth factor receptor (EGFR) [4, 5] and the anaplastic lymphoma kinase (ALK) gene rearrangement [6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.